Alimta To Replace Taxotere As Standard For Non-Small Cell Lung Cancer – Lilly
This article was originally published in The Pink Sheet Daily
Executive Summary
Lilly expects its non-small cell lung cancer therapy Alimta (pemetrexed) to replace Taxotere (docetaxel) as the standard of care in the second-line setting, Exec VP-Pharmaceutical Operations John Lechleiter said Jan. 11 at the J.P. Morgan health care conference in San Francisco
You may also be interested in...
Lilly’s Alimta Brochure Does Not Include Specific Indication, Says DDMAC
The firm pulled the patient brochure after receiving an untitled letter from FDA’s ad division.
Lilly’s Alimta Brochure Does Not Include Specific Indication, Says DDMAC
The firm pulled the patient brochure after receiving an untitled letter from FDA’s ad division.
Iressa Promotion Halted; AstraZeneca To Highlight Tarceva Survival Benefit
Gefitinib fails to demonstrate a survival benefit in the Iressa Survival Evaluation in Lung cancer confirmatory trial. AstraZeneca will meet with FDA to determine whether accelerated approval licensure of Iressa will be withdrawn, CEO McKillop says.